Joanna Huszno

Joanna Huszno

Auto-generated profile, based on publicly available information

Joanna Huszno

Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
JHJoanna Huszno
Joanna Huszno
EGEwa Grzybowska
Ewa Grzybowska
Tumor protein 53 (TP53) is a tumor suppressor gene that encodes tumor protein p53. Tumor protein p53 regulates the expression of target genes in response to cellular stress. Additionally, p53 participates in the regulation of cell cycle checkpoints, DNA repair and apoptosis. Mutations in the TP53 gene are associated with numerous types of human cancer, including breast cancer, sarcomas, brain tumors and adrenal cortical carcinomas. In breast cancer, TP53 mutations are a negative prognostic factor. Tumors with TP53 mutations are more likely to be aggressive (triple‑negative or human epidermal growth factor receptor 2‑positive breast cancer), and resistant to chemotherapy and radiotherapy. In addition to a well‑known TP53 mutation, a number of single nucleotide polymorphisms have been systematically identified and evaluated in human populations. In the present article, the role of TP53 mutations and polymorphisms in clinical practice and breast cancer treatment has been described. Additionally, the existing data on TP53 polymorphisms in breast cancer as prognostic and predictive factors have been summarized. A literature search of these topics was performed through PubMed and abstracts of the main cancer congresses in recent years.

8 October 2019 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
JHJoanna Huszno
Joanna Huszno
ZKZofia Kolosza
Zofia Kolosza
The aim of the present study was to assess the blood the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) as prognostic factors in breast cancer (BC) patients. A retrospective analysis of 436 BC patients who were treated at COI (Gliwice, Poland) between January 2005 and June 2018 was performed. The prognostic value [overall survival (OS)] of the pre-treatment PLR, NLR and MLR was assessed by univariate and multivariate analysis. The 5-year OS was lower in the NLR >2.65 compared with that in the NLR≤2.65 group (82.5 vs. 89.6%; P=0.053), and significantly lower in the subgroup of triple-negative breast cancer (TNBC; 70.3 vs. 89.3%; P=0.034) and in patients whose tumors had an estrogen receptor-negative [ER(−)] status (66.6 vs. 83.6%; P=0.018). The 5-year OS was lower in patients with PLR >190.9 compared with that in the PLR≤190.9 group (78.7 vs. 89.4%; P=0.020). A poor OS rate associated with an elevated PLR was also observed in the subgroups with TNBC (68.2 vs. 88.5%; P=0.032) and with ER(−) status tumors (57.7 vs. 83.6%, P=0.002). An elevated MLR (>0.28) was not associated with OS time (P=0.830). Multivariate analysis revealed that the NLR and PLR were insignificant negative prognostic factors, except for the subgroup of patients with ER(−) tumors, where an elevated NLR [hazard ratio (HR)=2.40; 95% confidence interval (CI): 1.20–4.80; P=0.013] and a higher PLR (HR=2.51; 95%CI: 1.23–5.14; P=0.012) were independent prognostic factors for poor OS together with lymph node metastasis ((HR=5.47; 95%CI: 2.46–12.15; P=0.0001 and HR=4.82; 95% CI: 2.15–10.78; P=0.0001), respectively. The present results revealed that an elevated NLR (>2.65) and PLR (>190.9) are associated with poor OS in BC patients. In the ER(−) subgroup of patients, an elevated NLR and PLR were significant independent prognostic factors. However, the MLR did not affect OS.

1 January 2013 in Central European Journal of Urology
Verified
Journal Article
Open access
JHJoanna Huszno
Joanna Huszno
DSDanuta Starzyczny–Słota
Danuta Starzyczny–Słota
MJMagdalena Jaworska
Magdalena Jaworska
ENElżbieta Nowara
Elżbieta Nowara
The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...

2 May 2019 in Oncology
Verified
Journal Article
Closed access
PDF file
JHJoanna Huszno
Joanna Huszno
ZKZofia Kolosza
Zofia Kolosza
JMJolanta Joanna Mrochem-Kwarciak
Jolanta Joanna Mrochem-Kwarciak
TRTomasz Rutkowski
Tomasz Rutkowski
KSKrzysztof Skladowski
Krzysztof Skladowski
Objective(s): The aim of this analysis was to evaluate the platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), platelets (PLT), and neutrophil level for their prognostic value in patients with metastatic renal cell carcinoma (mRCC). Materials: We retrospectively reviewed medical records of 141 patients with mRCC (2006–2016). Univariate and multivariate analyses were performed with the Cox proportional hazards regression model. The cutoff value of NLR was “elevated” as >3.68 and the PLR cutoff value was “elevated” as >144.4. Results: The median PFS and OS were shorter in elevated NLR and PLR. A higher value of PLT was associated with worse median OS and higher neutrophil level with worse OS and PFS. In multivariate analysis, higher NLR (p = 0.007) and PLR (p = 0.006) were independent prognostic factors for shorter OS together with BMI ≤30 (p = 0.004), higher Fuhrman grade (p = 0.0002), lower level of hemoglobin (p= 0.010), and ZUBROD 2 (p = 0.0002). Higher PLR (p = 0.0002) was an independent negative prognostic factor for PFS together with higher Fuhrman grade (p = 0.001), higher neutrophil level (p = 0.001), and lower lymphocyte level (p = 0.013). Conclusion: Elevated pretreatment NLR, PLR, PLT, and neutrophil count are associated with shorter OS and PFS in patients with mRCC. NLR and PLR are independent prognostic factors for OS. However, PLR and neutrophil count are independent prognostic factors for PFS.

28 November 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
JHJoanna Huszno
Joanna Huszno
ZKZofia Kołosza
Zofia Kołosza
EGEwa Grzybowska
Ewa Grzybowska
The presence of BRCA1 mutations is associated with an increased risk of breast and ovarian cancer. The present study compared clinicopathological characteristics and overall survival (OS) of hereditary and sporadic breast cancer. Using data collected from a previous study conducted between 2007‑2016 at the Maria Skłodowska Curie Cancer Center and Institute of Oncology (Gliwice, Poland), the prognostic factors and survival in 60 breast cancer mutation carriers were analyzed. A control group was selected from the breast cancer patients without BRCA mutations (n=386). BRCA mutation carriers had significantly worse survival when compared with non‑carriers (P=0.017). The 10‑year OS rate was 78.0% for all analyzed groups: 65.9% for BRCA mutation carriers and 81.1% for non‑carriers. In the univariate analyses, BRCA mutation carriers had a significantly higher risk of mortality in comparison to non‑carriers [hazard ratio (HR)=1.87; 95% confidence interval (CI) 1.08‑3.25]. Increased tumor size (HR=3.64), lymph node metastases (HR=2.45) and higher histological grade (HR=2.84) were significant factors for worse OS. Positive estrogen receptor status was associated with a better OS (HR=0.49, P=0.022). Age ≤40 years (HR=0.48, P=0.081) was an insignificantly favorable factor. The 10‑year survival rate was significantly decreased in patients with BRCA1 mutation. Therefore, negative factors for OS in mutation carriers included lymph nodes metastases, negative steroid receptor status and increased tumor size.

8 July 2022 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
JHJoanna Huszno
Joanna Huszno
ZKZofia Kołosza
Zofia Kołosza
JMJolanta Mrochem‑Kwarciak
Jolanta Mrochem‑Kwarciak
ETEwa Telka
Ewa Telka
BJBożena Jochymek
Bożena Jochymek
LMLeszek Miszczyk
Leszek Miszczyk
The aim of the present analysis was to evaluate the platelet‑lymphocyte ratio (PLR), neutrophil‑lymphocyte ratio (NLR), lymphocyte‑monocyte ratio (LMR), platelets (PLT) and neutrophil level for their prognostic values in patients with prostate cancer who had been treated with radiotherapy. A retrospective analysis of 152 patients who were treated in the Radiotherapy Department at Maria Sklodowska‑Curie National Research Institute of Oncology (Gliwice, Poland) between January 2012 and December 2014 was performed. The prognostic value (overall survival; OS) of the pre‑treatment PLR, NLR, LMR, PLT, neutrophil level and other laboratory factors such as: leukocyte, lymphocyte, monocyte, hemoglobin, RBC, prostate‑specific antigen level (PSA), Gleason score, age, smoking and comorbid condition were assessed using univariate analysis. The cut‑off point was determined for NLR as ‘elevated’ at >4.66, LMR >3.26 and the PLR was considered ‘elevated’ at >89.6. Median follow‑up was 4.9 years. The 5 and 7‑year OS rates were 81.5 and 72.2%, respectively. In univariate analysis higher NLR (P=0.007), higher level of PLT (P=0.004), higher level of neutrophils (P=0.013), elevated level of leukocyte (P=0.043) and lymphocyte (P=0.043) were factors significantly associated with decreased OS. No difference was found for PLR (P=0.308) and LMR (P=0.109). The other factor associated with decreased OS were: higher Gleason score (>7; P=0.005), higher PSA level (>20 ng/dl; P=0.0001), smoking (P=0.003) and older age (>70 years; P=0.018). In multivariate analysis, NLR, LMR, leukocyte and RBC were independently associated with prognosis in patients with prostate cancer. Elevated pre‑treatment NLR [hazard ratio (HR)=10.83; P=0.001), LMR (HR=3.14; P=0.007) and higher leukocyte level (HR=3.14; P=0.007) were independently associated with increased mortality risk. Overall, pre‑treatment NLR, PLR, leukocyte and RBC levels were revealed to be independent prognostic factors.